Progress on medication-related osteonecrosis of the jaw

doi:10.7518/hxkq.2018.05.019

Abstract

Abstract:

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of bisphosphonates (BPs) or other targeted agent therapies. MRONJ appears as exposed bone, pus, and swelling in the oral and maxillofacial regions. However, neither surgery nor conservative therapy can eliminate symptoms thoroughly. In addition to BPs, several antire-sorptive and antiangiogenic agents, such as denosumab and bevacizumab, as well as targeted agents, such as sunitinib and temsirolimus, can cause osteonecrosis of the jaw according to the literature. This review aims to summarize the research progress on these new drugs.

Key words: bisphosphonates, denosumab, bevacizumab, osteonecrosis

CLC Number:

R782.3⁺2

Qizhang Wang,Jiyuan Liu,Jian Pan. Progress on medication-related osteonecrosis of the jaw[J]. West China Journal of Stomatology, 2018, 36(5): 568-572.

References 39

[1]	Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003,61(9):1115-1117. doi: 10.1016/S0278-2391(03)00720-1 URL
[2]	Ruggiero SL, Dodson TB, Fantasia J , et al. American Asso-ciation of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update[J]. J Oral Maxillofac Surg, 2014,72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031 URL
[3]	Ruggiero SL, Dodson TB, Assael LA , et al. American Asso-ciation of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update[J]. J Oral Maxillofac Surg, 2010,35(3):119-130.
[4]	Bodem JP, Kargus S, Engel M , et al. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2015,43(7):1139-1143. doi: 10.1016/j.jcms.2015.05.019 URL
[5]	Klingelhöffer C, Zeman F, Meier J , et al. Evaluation of sur-gical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws[J]. J Cranioma-xillofac Surg, 2016,44(10):1694-1699. doi: 10.1016/j.jcms.2016.08.001 URL
[6]	Janovska Z, Mottl R, Slezak R . Experience with the treat-ment of bisphosphonate-related osteonecrosis of the jaw[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015,159(2):313-317. doi: 10.5507/bp.2013.069 URL
[7]	Kim KM, Park W, Oh SY , et al. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporos Int, 2014,25(5):1625-1632. doi: 10.1007/s00198-014-2622-8 URL
[8]	Cheung A, Seeman E . Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010,363(25):2473-2474. doi: 10.1056/NEJMc1002684 URL pmid: 20950167
[9]	Bagan J, Peydró A, Calvo J , et al. Medication-related osteo-necrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis[J]. Oral Dis, 2016,22(4):324-329. doi: 10.1111/odi.2016.22.issue-4 URL
[10]	Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL , et al. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials[J]. Clin Oral Implants Res, 2016,27(3):367-375.
[11]	Owosho AA, Blanchard A, Levi L , et al. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: a series of thirteen patients[J]. J Cra-niomaxillofac Surg, 2016,44(3):265-270. doi: 10.1016/j.jcms.2015.12.005 URL
[12]	Baron R, Ferrari S, Russell RG , Denosumab and bisphos-phonates: different mechanisms of action and effects[J]. Bone, 2011,48(4):677-692. doi: 10.1016/j.bone.2010.11.020 URL pmid: 21145999
[13]	Matsumoto A, Sasaki M, Schmelzeisen R , et al. Primary wound closure after tooth extraction for prevention of me-dication-related osteonecrosis of the jaw in patients under denosumab[J]. Clin Oral Investig, 2017,21(1):127-134. doi: 10.1007/s00784-016-1762-y URL
[14]	Henry D, Vadhan-Raj S, Hirsh V , et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors[J]. Sup-port Care Cancer, 2014,22(3):679-687. doi: 10.1007/s00520-013-2022-1 URL
[15]	Lee DK, Kim SH, You YS , et al. High dose intravitreal beva-cizumab for refractory pigment epithelial detachment in age-related macular degeneration[J]. Korean J Ophthalmol, 2016,30(4):265-271. doi: 10.3341/kjo.2016.30.4.265 URL
[16]	Estilo CL, Fornier M, Farooki A , et al. Osteonecrosis of the jaw related to bevacizumab[J]. J Clin Oncol, 2008,26(24):4037-4038. doi: 10.1200/JCO.2007.15.5424 URL pmid: 18711196
[17]	Magremanne M, Lahon M, De Ceulaer J , et al. Unusual bevacizumab-related complication of an oral infection[J]. J Oral Maxillofac Surg, 2013,71(1):53-55. doi: 10.1016/j.joms.2012.03.022 URL pmid: 22705223
[18]	Guarneri V, Miles D, Robert N , et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer[J]. Breast Cancer Res Treat, 2010,122(1):181-188. doi: 10.1007/s10549-010-0866-3 URL
[19]	Ramírez L, López-Pintor RM, Casañas E , et al. New non-bisphosphonate drugs that produce osteonecrosis of the jaws[J]. Oral Health Prev Dent, 2015,13(5):385-393. doi: 10.3290/j.ohpd.a34055 URL pmid: 25884045
[20]	Ponzetti A, Pinta F, Spadi R , et al. Jaw osteonecrosis asso-ciated with aflibercept, irinotecan and fluorouracil: attention to oral district[J]. Tumori, 2016,102(2):S74-S77.
[21]	Koch FP, Walter C, Hansen T , et al. Osteonecrosis of the jaw related to sunitinib[J]. J Oral Maxillofac Surg, 2011,15(1):63-66. doi: 10.1007/s10006-010-0224-y URL
[22]	Viviano M, Rossi M, Cocca S . A rare case of osteonecrosis of the jaw related to imatinib[J]. J Korean Assoc Oral Ma-xillofac Surg, 2017,43(2):120-124. doi: 10.5125/jkaoms.2017.43.2.120 URL pmid: 5410424
[23]	Marino R, Orlandi F, Arecco F , et al. Osteonecrosis of the jaw in a patient receiving cabozantinib[J]. Aust Dent J, 2015,60(4):528-531. doi: 10.1111/adj.12254 URL pmid: 25474298
[24]	Gnant M, Baselga J, Rugo HS , et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2[J]. J Natl Cancer Inst, 2013,105(9):654-663. doi: 10.1093/jnci/djt026 URL pmid: 23425564
[25]	Fusco V, Santini D, Armento G , et al. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology[J]. Expert Opin Drug Saf, 2016,15(7):925-935. doi: 10.1080/14740338.2016.1177021 URL pmid: 27074901
[26]	Owosho AA, Scordo M, Yom SK , et al. Osteonecrosis of the jaw a new complication related to Ipilimumab[J]. Oral Oncol, 2015,51(12):e100-e101. doi: 10.1016/j.oraloncology.2015.08.014 URL pmid: 26421864
[27]	Fusco V, Porta C, Saia G , et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bis-phosphonates and targeted agents: results of an italian mul-ticenter study and review of the literature[J]. Clin Genitourin Cancer, 2015,13(4):287-294. doi: 10.1016/j.clgc.2014.12.002 URL
[28]	Maluf G, Pinho MC, Cunha SR , et al. Surgery combined with LPRF in denosumab osteonecrosis of the jaw: case report[J]. Braz Dent J, 2016,27(3):353-358. doi: 10.1590/0103-6440201600662 URL pmid: 27224573
[29]	Lescaille G, Coudert AE, Baaroun V , et al. Clinical study evaluating the effect of bevacizumab on the severity of zole-dronic acid-related osteonecrosis of the jaw in cancer patients[J]. Bone, 2014,58:103-107. doi: 10.1016/j.bone.2013.10.002 URL
[30]	Koizumi M, Gokita T, Toda K . Impending atypical femoral fracture in patients with medullary thyroid cancer with ske-letal metastasis treated with long-term bisphosphonate and denosumab[J]. Clin Nucl Med, 2017,42(6):463-464. doi: 10.1097/RLU.0000000000001592 URL
[31]	Soós B, Vajta L, Szalma J . Sunitinib and zoledronic acid induced osteonecrosis of the jaw[J]. Orv Hetil, 2015,156(46):1865-1870.
[32]	Aghaloo T, Hazboun R, Tetradis S . Pathophysiology of osteo-necrosis of the jaws[J]. Oral Maxillofac Surg Clin North Am, 2015,27(4):489-496. doi: 10.1016/j.coms.2015.06.001 URL pmid: 4908822
[33]	Yang H, Pan H, Yu F , et al. A novel model of bisphospho-nate-related osteonecrosis of the jaw in rats[J]. Int J Clin Exp Pathol, 2015,8(5):5161-5167.
[34]	Sharma S, Guru SK, Manda S , et al. A marine sponge alka-loid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade[J]. Chem Biol Interact, 2017,275:47-60.
[35]	Wang H, Zhang CY, Ning ZY , et al. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling[J]. Int J Oncol, 2016,48(3):1229-1241. doi: 10.3892/ijo.2016.3326 URL pmid: 26782953
[36]	Santini D, Vincenz B, Dicuonzo G , et al. Zoledronic acid induces significant and long-lasting modifications of circu-lating angiogenic factors in cancer patients[J]. Clin Cancer Rese, 2003,9(8):2893-2897.
[37]	Ohlrich EJ, Coates DE, Cullinan MP , et al. The bisphospho-nate zoledronic acid regulates key angiogenesis-related genes in primary human gingival fibroblasts[J]. Arch Oral Biol, 2016,63:7-14. doi: 10.1016/j.archoralbio.2015.11.013 URL
[38]	Gao SY, Zheng GS, Wang L , et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts for-mation and secretion of PDGF-BB[J]. PLoS One, 2017,12(6):e0179248. doi: 10.1371/journal.pone.0179248 URL
[39]	Bettini G, Blandamura S, Saia G , et al. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease pro-cess[J]. BMJ Case Rep, 2012, pii: bcr2012007284. doi: 10.1136/bcr-2012-007284. doi: 10.1136/bcr-2012-007284 URL pmid: 4543697